Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization | ADTX Stock News

Author's Avatar
Jul 07, 2025
Article's Main Image
  • Aditxt, Inc. (ADTX, Financial) launches bitXbio™, a strategy integrating Bitcoin-backed treasury to boost biotech commercialization.
  • The firm plans to utilize a Bitcoin reserve and an equity line facility to support monetization events starting in 2026.
  • A potential initial public offering for Pearsanta is part of Aditxt's 2026 monetization strategy.

Aditxt, Inc. (ADTX), a company focused on accelerating health innovations, has unveiled its new bitXbio™ strategy. This next-generation capitalization and monetization plan integrates a Bitcoin-backed treasury strategy to enhance Aditxt’s financial ecosystem and support its biotech commercialization efforts. The initiative aligns with the company's plans to meet prospective monetization opportunities projected to begin in 2026.

The bitXbio strategy involves establishing a Bitcoin reserve, contingent upon the availability of funds, to align Aditxt's market value and unlock new opportunities within digital asset economies. This approach aims to broaden the capital ecosystem while boosting the company's balance sheet and enterprise value.

Additionally, Aditxt will leverage its equity line facility to strategically deploy capital for financial obligations and support its commercialization roadmap. The company has about $125 million in available capital under its common stock purchase agreement, allowing them to sell up to 50 million shares of common stock as per its SEC registration statement effective June 30, 2025.

Looking into 2026, Aditxt plans to initiate an initial public offering for Pearsanta as part of its broader monetization strategy. This reflects Aditxt's vision to build a global, socially driven biotech platform capable of commercializing and monetizing innovation through digital capitalization.

Aditxt, Inc. continues to focus on advancing its two primary health programs in autoimmunity and early disease detection while also planning an expansion into women's health through the intended acquisition of Evofem. The closing of this transaction, expected in the latter half of 2025, remains subject to specific conditions, including securing sufficient funds for the $17 million cash payment obligations.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.